Quarterly Activities Report and Appendix 4C

Bio-Gene Technology Limited (**ASX:BGT**, "**Bio-Gene**" or "**the Company**"), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides an update on activities for the quarter ended 30 June 2026 (Q4 FY26) and to date.

Q4 FY26 Highlights

- **Expanded Flavocide® and Qcide® mosquito vector control evaluation into Asia, targeting species responsible for dengue, chikungunya and Zika**
- **Initial WHO-aligned testing in Singapore and the wider region expected to be completed during Q4 CY2026**
- **A wide range of activities have been undertaken to progress the opportunity to launch Qcide in Japan with Sumitomo Corporation and Nakashima Trading Co**
- **The OECD 424 and OCED 443 toxicity studies are progressing, with results expected in September 2026**
- **Key US patent allowed for synergistic Flavocide combinations with permethrin and pyrethrin, extending protection to 2040 upon grant**
- **Peter May received the Envu Excellence Award for recognition of outstanding service to the Australian commercial pest management industry**
- **$3.275 million in capital raised to support Flavocide® and Qcide® programs**

Operational Activities

Flavocide and Qcide vector control evaluation expands into Asia

In May 2026, Bio-Gene announced the expansion of its mosquito vector control development program into Asia, with both Flavocide and Qcide to be evaluated against several mosquito species responsible for transmitting serious human diseases.

The program will assess the susceptibility of prevalent mosquito species found in Singapore and other parts of the region to Bio-Gene's two proprietary insecticidal active compounds. Testing will be conducted in accordance with World Health Organisation guidelines, with the initial phase expected to be completed during the fourth quarter of calendar 2026. The data generated will help inform Bio-Gene's commercialisation strategy and assess the potential use of Flavocide and Qcide within regional vector control programs.

The evaluation will focus on three important mosquito species: *Aedes aegypti*, *Aedes albopictus* and *Culex quinquefasciatus*. These species are associated with the transmission of mosquito-borne diseases including dengue fever, chikungunya fever and Zika virus infection. Other diseases capable of being transmitted by mosquitoes found in the region include West Nile virus, Japanese encephalitis and St. Louis encephalitis, although these diseases are not generally endemic across the targeted markets.

Singapore and other Asian countries experience a substantial and ongoing burden from mosquito-borne disease. Singapore has recorded annual dengue case numbers ranging from approximately 3,990 to 13,651 over the previous seven years, demonstrating the continued need for effective and sustainable mosquito control solutions.

The regional evaluation represents an important opportunity for Bio-Gene as resistance to established insecticides continues to increase among mosquito populations. This resistance can reduce the effectiveness of existing control products and creates a need for insecticides with new modes of action that can be incorporated into Integrated Pest Management programs.

Flavocide and Qcide produce their insecticidal effects through an innovative mode of action that differs from currently available insecticide classes. This gives the products the potential to provide new control options for endemic mosquito populations, including populations that have developed resistance to commonly used insecticides.

Successful completion of the evaluation will provide Bio-Gene with further data regarding the efficacy of Flavocide and Qcide against regionally important mosquito species and support an assessment of their suitability as new nature-derived mosquito control agents. The results will also guide future development, regulatory and commercialisation activities for the products across Asian public health and vector control markets.

Development of Qcide for use in Japan against household nuisance insects

As announced in March 2026, Bio-Gene is working with Sumitomo Corporation and Nakashima Trading Co. on the opportunity to develop and market a range of insecticide products containing Qcide. These products will be launched for use in Japan's household nuisance insect pest market, with product launch currently targeting late 2026 following all required approvals.

Significant work has been undertaken during Q4 FY26 and to date related to this opportunity, including preparation of draft commercial terms, initiating the application for the approval to import and supply Qcide into Japan, preparation of various prototype formulations and assessment of different potential packaging options.

Ongoing toxicity studies (OECD 424 and OECD 443)

The Flavocide acute neurotoxicity study (OECD 424) and the extended one-generation reproductive toxicity study (OECD 443) announced in February 2026 are ongoing. Based on progress by the contract research organisations undertaking these two studies, the preliminary report for the OECD 424 study is expected to be received in September 2026. This report was originally expected in May 2026 but was delayed due to a system error with the software used in one component of the study, which required updating and validation before the study could continue. This delay will not have any impact on the anticipated filing date for the Company's initial Flavocide regulatory dossier with the APVMA. The preliminary report for the OECD 443 study is also expected in September 2026.

US patent allowed for key Flavocide insecticide combinations

During the quarter, Bio-Gene received a notice of allowance from the United States Patent and Trademark Office for a key patent covering the use of flavesone, the active compound in Flavocide, in synergistic combination with the established insecticidal actives permethrin and pyrethrin.

The notice confirms that the patent application has successfully completed the substantive US examination process and has been approved for grant. Formal notification of the patent grant was expected within approximately two to four months of the announcement, following which the intellectual property protection will extend in the United States until 2040.

The patent strengthens Bio-Gene's intellectual property position around the use of Flavocide in combination products. Synergistic combinations are designed to produce a greater insecticidal effect than the individual active ingredients, potentially enabling improved efficacy and supporting the development of differentiated pest control products.

Permethrin is representative of a group of synthetic pyrethroid compounds, and pyrethrins are a natural form of this class of insecticides that are used across a range of pest management applications. Patent protection covering flavesone in combination with permethrin/pyrethrins provides Bio-Gene with an opportunity to develop and commercialise products that combine Flavocide's novel properties with established insecticide chemistries. The protected combinations may also support potential licensing and product development arrangements with commercial partners.

Equivalent patents covering these and other important insecticide combinations have already been granted in Australia, Japan and New Zealand, as well as across 22 member states of the African Regional Intellectual Property Organisation. Related applications remain under examination in additional jurisdictions.

The US allowance represents a further expansion of Bio-Gene's global patent portfolio and supports the Company's strategy of building commercially valuable intellectual property around Flavocide. The patent estate is intended to protect Bio-Gene's technology while creating licensable assets that can be incorporated into products developed with industry partners across crop protection, public health and consumer pest control markets.

Peter May receives the Envu Australian Individual Excellence Professional Pest Management Award 2026

Peter May, Bio-Gene's Executive Director – Research & Development, recently attended the FAOPMA (**Federation of Asia & Oceania Pest Managers Associations**) Pest Summit in Auckland, NZ, representing Bio-Gene and supporting AEPMA (Australian Environmental Pest Managers Association) in this collaborative event hosted by the Pest Managers Association of

New Zealand (PMANZ). During the Summit, Peter was presented with the Envu Australian Individual Excellence Professional Pest Management Award 2026 in recognition of "*outstanding service to the commercial pest management industry, reflecting excellence, professionalism, and commitment beyond expectation*". The Award is sponsored by Envu and AEPMA and acknowledges Peter's current and past involvement and contribution to the Australian pest management industry, including his current role as Secretary to the Queensland Branch of AEPMA. His attendance at this event enabled engagement with current Bio-Gene collaborators such as Envu, as well as other supplier and service companies involved in regional markets where Bio-Gene products can be used.

Investor presentations and webinar

In April 2026, Bio-Gene presented at the Ignite Investment Summit in Singapore and in June 2026, Bio-Gene hosted an investor webinar providing shareholders and investors with an update on the Company's activities following its capital raising comprising a Placement and partially underwritten Share Purchase Plan (details below).

The webinar was presented by Managing Director and CEO Tim Grogan and included an overview of Bio-Gene's recent progress, the intended use of funds raised and the Company's plans to advance the development and commercialisation of Flavocide and Qcide. The presentation was followed by a question-and-answer session with investors.

A replay of the investor webinar is available at: https://youtu.be/mqMKoS_QUYo

Fundraising Activities

$3.275 million capital raising supports Flavocide and Qcide programs

During the quarter, Bio-Gene secured binding commitments to raise approximately $2.775 million through a Placement to professional and sophisticated investors at an issue price of $0.025 per share.

The Placement comprised an initial tranche of approximately $1.906 million issued under the Company's existing placement capacity, together with a second tranche of approximately $0.869 million subject to shareholder approval at the General Meeting planned for 5 August 2026. Placement participants are also entitled, subject to approval, to receive one free-attaching option for every two shares issued, exercisable at $0.035 and expiring on 15 October 2027.

Funds raised are supporting completion of the remaining safety studies required for Bio-Gene's first Australian regulatory application for the Flavocide active constituent. Proceeds are also being used to increase production of Qcide, support product development and commercial partnering activities, fund strategic projects and provide additional working capital.

Bio-Gene also conducted a Share Purchase Plan underwritten to $500,000. Applications totalling $119,500 were received, with the remaining $380,500 shortfall expected to be placed under the underwriting agreement, subject to shareholder approval.

Financials

Bio-Gene had a cash balance of $1,940,000 as of 30 June 2026.

Payments to related parties, comprising compensation in the form of salary and superannuation paid to executive and non-executive directors, were $190,689 for the second calendar quarter of 2026.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

To subscribe to Bio-Gene's announcements and other forms of email communication, please visit this page of our website.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN	**Quarter ended ("current quarter")**
32 071 735 950	**30 June 2026**

Consolidated statement of cash flows			**Current quarter $A'000**	**Year to date (12 Months) $A'000**
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		90	593
1.2	Payments for			
	(a)	commercialisation expenses	(65)	(399)
	(b)	research and development	(320)	(1,639)
	(c)	intellectual property	(149)	(315)
	(d)	professional services	(38)	(112)
	(e)	directors' expenses	(47)	(187)
	(f)	administration and corporate costs	(109)	(471)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		2	22
1.5	Interest and other costs of finance paid		-	-
1.6	Income taxes paid		-	-
1.7	Government grants and tax incentives		-	-
1.8	Other (R&D Refund)		-	520
1.9	**Net cash from / (used in) operating activities**		**(636)**	**(1,988)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	2,026	2,991
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(160)	(185)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(51)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (share proceeds received in advance)	35	35
3.10	**Net cash from / (used in) financing activities**	**1,901**	**2,790**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	674	1,138
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(636)	(1,988)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,901	2,790
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,940**	**1,940**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	389	124
5.2	Call deposits	1,551	551
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,940**	**674**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	191
6.2	Aggregate amount of payments to related parties and their associates included in item 2	N/A

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Note 6.1: Director's fees paid to Directors or their related entities plus remuneration paid to Executive Directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	N/A	N/A
7.2	Credit standby arrangements	N/A	N/A
7.3	Other (please specify)	N/A	N/A
7.4	**Total financing facilities**	**N/A**	**N/A**
7.5	**Unused financing facilities available at quarter end**		**N/A**
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(636)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,940
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**1,940**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	3.1

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: The Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year-to-date basis. Movements disclosed for the current quarter have been correctly calculated.